Navigation Links
Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
Date:3/19/2013

oss for the year ended December 31, 2012 was $15.6 million, or $0.33 per share (basic and diluted), compared to a net loss of $13.3 million, or $0.47 per share (basic and diluted), for the same period in 2011.

R&D expenses for the year ended December 31, 2012 were $8.1 million, an increase of $2.3 million, or 41%, compared to $5.8 million for the same period in 2011. The increase was due to a $1.2 million increase in personnel costs, a $0.6 million increase in external clinical study fees and expenses and a $0.5 million increase in external nonclinical study fees. The increase in personnel costs was primarily related to additional clinical and research-related manufacturing staff hired in 2012, including relocation and recruitment costs for our new Chief Medical Officer. The increase in external clinical study fees and expenses was related primarily to a $0.8 million increase in clinical consulting and phase 3 study planning expenses for MST-188, offset by a $0.2 million decrease in clinical consulting expenses for ANX-514 and ExelbineTM.  The increase in external nonclinical study fees and expenses was related primarily to a $2.0 million increase in research-related manufacturing activities and regulatory affairs-related consulting expenses for MST-188 and a $0.7 million increase in research-related manufacturing activities for ANX-514, offset by a $2.2 million decrease in commercial-readiness manufacturing activities for Exelbine.  Due to its focus on MST-188, the Company elected to discontinue independent development of its ANX-514 and Exelbine programs in 2012 and 2011, respectively.

SG&A expenses for the year ended December 31, 2012 were $7.5 million, an increase of $0.3 million, or 5%, compared to $7.2 million for the same period in 2011. The net increase resulted from a $0.7 million increase in personnel costs, mainly due to additional staff hired in 2012, and a $0.5 million increase in share-based compensation expe
'/>"/>

SOURCE Mast Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Achieves ISO 13485 Certification
2. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
3. Echo Therapeutics Appoints Robert Doman to Board of Directors
4. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
5. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
6. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
7. PTC Therapeutics Closes $60 Million Private Financing
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
10. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
(Date:8/29/2014)... PASO ROBLES, Calif. , Aug. 29, 2014 /PRNewswire/ ... launch of its new website design . The ... an overhaul that showcases the company,s new services and ... By implementing a new streamlined design, viewers can ... deliver metrics for health care practices and create a ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ –  ... PHG AEX: PHIA) today announced ... Society of Cardiology (ESC) Congress 2014 ... range of its cardiology solutions serving clinicians and ... prevention and diagnosis, to treatment, ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5
... FRANKLIN LAKES, N.J., Nov. 3, 2010 BD (Becton, Dickinson ... medical technology company, today reported quarterly revenues of $1.873 billion ... an increase of 1.0 percent from the prior-year period, or ... For the full fiscal year ended September 30, 2010, BD ...
... EATONTOWN, N.J., Nov. 3, 2010 Osteotech, Inc. (Nasdaq: ... field of biologic products for regenerative healing, announced today ... has been selected to receive the Research and Development ... Award in the medical category.  Osteotech was chosen from ...
Cached Medicine Technology:BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 2BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 3BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 4BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 5BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 6BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 7BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 8BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 9BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 10BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 11BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 12BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 13BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 14BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 15BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 16BD Announces Results for 2010 Fourth Fiscal Quarter and Full Year 17Osteotech's Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council 2Osteotech's Plexur M® Technology Wins Thomas Alva Edison Patent Award from the New Jersey Research and Development Council 3
(Date:8/29/2014)... have been hospitalized for a burn as a child experience ... to new research at the University of Adelaide . ... been conducted by the University,s Centre for Traumatic Stress Studies. ... some form of mental illness and 30% suffered depression at ... in the journal Burns , also found ...
(Date:8/29/2014)... disease outbreaks across the Arabian Peninsula and spread to ... the lives of several hundred people since its discovery ... puzzled over how easily the pathogen spreads from human ... virologists from the University of Bonn have now come ... of human transmission is low. Still, a third of ...
(Date:8/29/2014)... As a chiropractic physician and medical doctor an ... direct connection between the condition of the feet and ... shoe inserts and orthotics weren’t satisfying my patients, I ... said. , Customizable to a user’s needs, the patent-pending ... in order to help prevent pain in the foot, ...
(Date:8/29/2014)... HealthDay Reporter , THURSDAY, Aug. 28, ... days of the Ebola outbreak in West Africa has given ... Researchers report in the Aug. 28 online issue of ... The Ebola strains responsible for the current outbreak ... first recorded outbreak of Ebola in central Africa in 1976. ...
(Date:8/29/2014)... (HealthDay News) -- The way that parents respond to ... a new study suggests. Over six months, researchers ... during free play. The sessions were 30 minutes long ... months old at the start of the study. ... infants began to form complex sounds. The babies whose ...
Breaking Medicine News(10 mins):Health News:Intervention needed for survivors of childhood burns 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Gene Research Yields Insights Into Ebola Virus 2Health News:Gene Research Yields Insights Into Ebola Virus 3Health News:Encouraging Your Baby's Babbling May Speed Language Development 2
... Center researchers have discovered that bortezomib, a promising cancer ... tumor cells by revving up the action of a ... suggest a novel treatment strategy that might someday prove ... into overdrive, so that they self-destruct. , The U-M ...
... 20 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), a biomaterials ... drug delivery products, today,announced that President and CEO Robert ... Fourth Annual Healthcare Conference at the Palace,Hotel in New ... p.m. EST. Lazard Capital Markets will host a ...
... Again: MAGNETOM Verio Brings High-, Resolution MRI ... Delivers the Newest Technology ... 20 Siemens Medical,Solutions (http://www.usa.siemens.com/medical ) is once ... services with the introduction of two,new magnetic resonance imaging ...
... KILLING US with cancers of the prostate, ... kidney, bone, etc? by Randall Dale Chipkar, MISSISSAUGA, ... motorcyclists to protect themselves. In his just released book,MOTORCYCLE ... He asks, "Are unsuspecting riders at risk for cancer,development ...
... protein albumin suggests worsening coronary artery disease, study finds ... small amount of a protein called albumin in the ... their risk of cardiovascular death, say U.S. researchers. , ... age 50 and older, with stable coronary artery disease ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac,surgery products ... the,19th Annual Piper Jaffray Health Care Conference at the ... 2007, at 8:30 a.m. Eastern Time.,Michael Dale, President and ... Company,s historical financial results and overall business strategy. ...
Cached Medicine News:Health News:Cancer drug works by overactivating cancer gene 2Health News:Cancer drug works by overactivating cancer gene 3Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 2Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 3Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 4Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 5Health News:A Magnetic Presence: Siemens New MRI Systems Pulling More Patients Toward the Benefits of MR Imaging 6Health News:New Book Links Motorcycle Radiation to Cancer Risk 2Health News:Urine Test Results Can Point to Heart Dangers 2Health News:ATS Medical to Present at the 19th Annual Piper Jaffray Health Care Conference 2
Ad-Techs Epidural Peg Electrodes feature a silicone-insulated titanium contact. To accommodate varying skull thicknesses, the post lengths range in length from 4 to 16 mm. The connecting lead wires e...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
... provide you with an alternative method for ... proven design as Ad-Techs Spencer Probe Depth ... an introducing needle instead of a stylet. ... 3 to 6 platinum recording contacts, 5.0 ...
... is designed for laboratories looking for time ... in system operation in terms of easy ... calibration and on-board stability., ,URISYS 2400 ... enhanced walk-away capability for medium to high ...
Medicine Products: